TheEdgeResearch
Home / Stocks / NVCN

Neovasc Inc. (NVCN)

NASDAQ Healthcare Medical - Devices
$30.03 ▲ +0.00%
Market Cap
$82.9M
Sector
Healthcare
Industry
Medical - Devices
Beta
2.01
52-Wk Range
4.585-30.07
CEO
Fredericus A. Colen
Country
CA
Currency
USD

Neovasc Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Richmond, BC, CA. The stock last traded at $30.03, up 0.00% on the session, giving a market capitalisation of $82.9M. On trailing twelve-month figures it carries a trailing P/E of -1.99, a net margin of -1082.9%. Its beta of 2.01 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-1.99
Price / Sales
21.78
Price / Book
5.18
EV / EBITDA
-1.78
Gross margin
79.7%
Operating margin
-886.7%
Net margin
-1082.9%
Return on equity
—
Debt / equity
0.82
Current ratio
2.96
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
49
IPO date
2001-05-23
Headquarters
Richmond, BC, CA
About Neovasc Inc.

Neovasc Inc. is a specialized medical technology enterprise focused on the development, production, and worldwide distribution of products for the cardiac health sector, with a significant presence across Europe and other international markets. The company's key innovations feature the Tiara system, an advanced transcatheter technology for managing mitral valve disease, and the Neovasc Reducer, which offers a therapeutic option for patients suffering from refractory angina. Founded in 2000, the organization initially operated as Medical Ventures Corp. before adopting the name Neovasc Inc. in July 2008. Its corporate headquarters are situated in Richmond, Canada.

Comparable companies

Neovasc Inc. is most often compared with the following Healthcare names:

ASXCBLIIGMSIMDXJBIOLFWDNVNOZOMZYNE
More research on NVCN
NVCN technical analysis NVCN TheEdge Score Compare against peers
Open full interactive analysis & DCF →